Treatment of cutaneous T cell lymphoma

1 Views
administrator
administrator
08/09/23

Dr Duvic speaks with ecancertv at WCCS 2016 about mogamulizumab, an anti-CCR4 engineered antibody for treatment of cutaneous T cell lymphoma, also known as Sézary syndrome.

She reports on results from a phase I/II trial in which patient response rate reached 37%, and describes upcoming trials for mogamulizumab, with considerations of international approval and possible combination/complementary therapies.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next